RPL17

Large ribosomal subunit protein uL22 · P18621 · RPL17 on Sugi Atlas →

3,677 patent compounds predicted against RPL17, 1,927 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL17 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer	PHASE1/PHASE2	COMPLETED
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation	nan	COMPLETED
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome	nan	COMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome	nan	RECRUITING
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma	nan	WITHDRAWN
Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants	nan	COMPLETED
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Mitoquines in COPD	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RPL17 binder may also engage these)

Protein	Name	Similarity
Q9CPR4	—	1.000	Q9CPR4 →
Q3T025	—	1.000	Q3T025 →
Q5XTY7	—	1.000	Q5XTY7 →
P24049	—	1.000	P24049 →
Q1HR65	—	1.000	Q1HR65 →
G1SCJ6	—	1.000	G1SCJ6 →
Q93VI3	—	1.000	Q93VI3 →
Q5MIR6	—	0.999	Q5MIR6 →
A2I3Y6	—	0.999	A2I3Y6 →
Q9BL19	—	0.998	Q9BL19 →
Q29IM3	—	0.998	Q29IM3 →
P35267	—	0.997	P35267 →
Q9W3W8	—	0.997	Q9W3W8 →
Q09JW2	—	0.996	Q09JW2 →
Q5UAS2	—	0.996	Q5UAS2 →
Q4UF75	—	0.996	Q4UF75 →
Q6XJ13	—	0.996	Q6XJ13 →
Q4GXH5	—	0.996	Q4GXH5 →
Q5MGD1	—	0.995	Q5MGD1 →
Q5I5J1	—	0.995	Q5I5J1 →
A8CAG3	—	0.994	A8CAG3 →
Q4PM54	—	0.994	Q4PM54 →
P51413	—	0.994	P51413 →
P35266	—	0.994	P35266 →
A0NGY0	—	0.994	A0NGY0 →
Q4KTG9	—	0.993	Q4KTG9 →
Q6BM53	—	0.993	Q6BM53 →
Q59TE0	—	0.993	Q59TE0 →
P05740	—	0.993	P05740 →
O59794	—	0.993	O59794 →